INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC
Werte in diesem Artikel
NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Teladoc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On February 20, 2025, Blue Orca Capital ("Blue Orca") published a report on Teladoc, alleging that the Company has misled investors about its BetterHelp platform and financial reporting. The report claims that BetterHelp has used AI-generated responses in place of licensed therapists without proper disclosures to investors and patients and, among other allegations, accuses Teladoc of inflating profitability by shifting R&D expenses.
Follow publication of the Blue Orca report, Teladoc's stock price fell $2.26 per share, or 16.41%, over the following two trading sessions, to close at $11.51 per share on February 21, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-teladoc-health-inc---tdoc-302390349.html
SOURCE Pomerantz LLP
Ausgewählte Hebelprodukte auf Teladoc
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Teladoc
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Teladoc Inc
Analysen zu Teladoc Inc
Datum | Rating | Analyst | |
---|---|---|---|
02.11.2018 | Teladoc Buy | Chardan Capital Markets | |
03.08.2018 | Teladoc Buy | Chardan Capital Markets | |
05.06.2018 | Teladoc Buy | Canaccord Adams | |
15.03.2018 | Teladoc Hold | Deutsche Bank AG | |
28.02.2018 | Teladoc Buy | Chardan Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
02.11.2018 | Teladoc Buy | Chardan Capital Markets | |
03.08.2018 | Teladoc Buy | Chardan Capital Markets | |
05.06.2018 | Teladoc Buy | Canaccord Adams | |
28.02.2018 | Teladoc Buy | Chardan Capital Markets | |
08.12.2017 | Teladoc Buy | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
15.03.2018 | Teladoc Hold | Deutsche Bank AG | |
18.09.2017 | Teladoc Neutral | Robert W. Baird & Co. Incorporated |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Teladoc Inc nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen